

# James L Gulley

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5539410/publications.pdf>

Version: 2024-02-01

486  
papers

20,973  
citations

11639

70  
h-index

16164

124  
g-index

496  
all docs

496  
docs citations

496  
times ranked

19663  
citing authors

#	ARTICLE	IF	CITATIONS
1	Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. <i>Journal of Nuclear Medicine</i> , 2022, 63, 59-68.	2.8	61
2	Dual inhibition of TGF $\beta$ 2 and PD $\beta$ 1: a novel approach to cancer treatment. <i>Molecular Oncology</i> , 2022, 16, 2117-2134.	2.1	53
3	Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia. , 2022, 10, e003392.		34
4	A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer. <i>Oncologist</i> , 2022, 27, 198-209.	1.9	18
5	A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1). <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 735-740.	2.0	12
6	MPAPASS software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays. <i>Cell Reports Methods</i> , 2022, 2, 100136.	1.4	8
7	OUP accepted manuscript. <i>Oncologist</i> , 2022, 27, e353-e356.	1.9	2
8	Long-term avelumab in advanced non-small-cell lung cancer: summaries and <i>post hoc</i> analyses from JAVELIN Solid Tumor. <i>Future Oncology</i> , 2022, 18, 1333-1342.	1.1	1
9	Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival. , 2022, 10, e003302.		16
10	Safety evaluation of M9241 in combination with docetaxel in metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 93-93.	0.8	3
11	CAR T cells reach clinical milestone in prostate cancer. <i>Nature Medicine</i> , 2022, , .	15.2	3
12	Tumor in the Crossfire: Inhibiting TGF $\beta$ 2 to Enhance Cancer Immunotherapy. <i>BioDrugs</i> , 2022, 36, 153-180.	2.2	19
13	Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunity. <i>JCI Insight</i> , 2022, 7, .	2.3	5
14	Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa. , 2022, 10, e004601.		8
15	A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide. <i>Oncologist</i> , 2022, 27, 718-e694.	1.9	3
16	Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGF $\beta$ 2RII agent: Current status. <i>Experimental Biology and Medicine</i> , 2022, 247, 1124-1134.	1.1	7
17	Celebrating a decade of the <i>Journal for ImmunoTherapy of Cancer</i> . , 2022, 10, e005207.		0
18	Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF $\beta$ 2 blockade in HPV-unrelated head and neck cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	18

#	ARTICLE	IF	CITATIONS
19	In Reply. <i>Oncologist</i> , 2021, 26, e192-e193.	1.9	0
20	Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response. <i>Clinical Cancer Research</i> , 2021, 27, 429-437.	3.2	22
21	Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2021, 127, 435-444.	1.3	7
22	Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1391-1398.	3.2	20
23	Deep Learning Based Staging of Bone Lesions From Computed Tomography Scans. <i>IEEE Access</i> , 2021, 9, 87531-87542.	2.6	12
24	Neoadjuvant Immunotherapy: An Evolving Paradigm Shift?. <i>Journal of the National Cancer Institute</i> , 2021, 113, 799-800.	3.0	10
25	A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prostvac in metastatic hormone-sensitive prostate cancer (mHSPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS192-TPS192.	0.8	4
26	Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis. , 2021, 9, e002252.		1
27	Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma. , 2021, 9, e002097.		28
28	Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivolpi) for metastatic genitourinary tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3-3.	0.8	7
29	Abstract IA07: The QuEST for an effective immunotherapy for prostate cancer. , 2021, , .		0
30	Anaplastic features (AnaF) and DNA-damage repair pathway (DDR) mutations in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 92-92.	0.8	1
31	Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma. <i>Oncologist</i> , 2021, 26, e847-e858.	1.9	31
32	Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer. , 2021, 9, e001556.		9
33	Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC). , 2021, 9, e002374.		25
34	Interrogation of the cellular immunome of cancer patients with regard to the COVID-19 pandemic. , 2021, 9, e002087.		7
35	Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. <i>European Urology</i> , 2021, 80, 746-757.	0.9	50
36	Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF- $\beta$ 2 and PD-L1, in cervical cancer: Data from phase 1 and phase 2 studies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5509-5509.	0.8	10

#	ARTICLE	IF	CITATIONS
37	Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF- $\beta$ 2 and PD-L1, in advanced squamous cell carcinoma of the head and neck (SCCHN).. Journal of Clinical Oncology, 2021, 39, 6020-6020.	0.8	4
38	A phase 1 open label trial of intravenous administration of MVA-BN-Brachyury vaccine in patients with advanced cancer.. Journal of Clinical Oncology, 2021, 39, 2617-2617.	0.8	0
39	Phase II evaluation of the triple combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16 positive malignancies.. Journal of Clinical Oncology, 2021, 39, 2501-2501.	0.8	14
40	Patients with undetectable PSA 2 years after docetaxel for metastatic castration sensitive prostate cancer (mCSPC).. Journal of Clinical Oncology, 2021, 39, e17044-e17044.	0.8	1
41	Anaplastic Features in Advanced Prostate Cancer With and Without DNA Damage Repair Mutations. Clinical Genitourinary Cancer, 2021, 19, e352-e359.	0.9	0
42	A phase I study of bintrafusp alfa (M7824) and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in adults with metastatic non-prostate genitourinary malignancies.. Journal of Clinical Oncology, 2021, 39, TPS4599-TPS4599.	0.8	3
43	A phase I/II study of bintrafusp alfa and NHS-IL12 in combination with docetaxel in adults with metastatic castration sensitive (mCSPC) and castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, TPS5096-TPS5096.	0.8	3
44	First-in-human phase I/II trial of PRGN-2009 vaccine as monotherapy or with bintrafusp alfa in patients with recurrent/metastatic (R/M) human papillomavirus (HPV)-associated cancers (HPVC) and as neoadjuvant/induction therapy in locoregionally advanced (LA) HPV oropharyngeal (OP) and sinonasal (SN) squamous cell cancer (SCC).. Journal of Clinical Oncology, 2021, 39, TPS6092-TPS6092.	0.8	2
45	CD4+ T-cell count eligibility by HIV status among participants receiving immunotherapy for cancer diagnoses.. Journal of Clinical Oncology, 2021, 39, 12104-12104.	0.8	1
46	Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy. , 2021, 9, e002605.		7
47	Dual PD-L1 and TGF- $\beta$ blockade in patients with recurrent respiratory papillomatosis. , 2021, 9, e003113.		12
48	9570 Long-term follow-up of patients (pts) with human papillomavirus (HPV)-associated malignancies treated with bintrafusp alfa, a bifunctional fusion protein targeting TGF- $\beta$ 2 and PD-L1. Annals of Oncology, 2021, 32, S829.	0.6	6
49	Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer. , 2021, 9, e003238.		19
50	605P Analysis of serial PET imaging and paired Tc99 scans in metastatic castration resistant prostate cancer (mCRPC) treated with enzalutamide. Annals of Oncology, 2021, 32, S647.	0.6	0
51	MP16-14 CLINICAL OUTCOMES OF A RANDOMIZED, PROSPECTIVE, PHASE II STUDY TO DETERMINE THE EFFICACY OF BACILLUS CALMETTE-GUERIN (BCG) GIVEN IN COMBINATION WITH PANVAC VERSUS BCG GIVEN ALONE IN ADULTS WITH HIGH GRADE BCG-REFRACTORY NON-MUSCLE INVASIVE BLADDER CANCER. Journal of Urology, 2021, 206, .	0.2	4
52	A comparison of $^{18}\text{F}$ -DCFPyL, $^{18}\text{F}$ -NaF and $^{18}\text{F}$ -FDG PET/CT in a prospective cohort of men with metastatic prostate cancer. Journal of Nuclear Medicine, 2021, , jnumed.121.262371.	2.8	7
53	A rare insight into the immunosuppressive landscape of prostate cancer bone metastases. Cancer Cell, 2021, 39, 1450-1452.	7.7	2
54	Resistance to Immunotherapy: Mechanisms and Means for Overcoming. Advances in Experimental Medicine and Biology, 2021, 1342, 45-80.	0.8	2

#	ARTICLE	IF	CITATIONS
55	Phase I neoadjuvant study of intravesical recombinant fowlpox-GM-CSF (rF-GM-CSF) or fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinoma. <i>Cancer Gene Therapy</i> , 2020, 27, 438-447.	2.2	4
56	A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer. <i>Oncologist</i> , 2020, 25, 479-e899.	1.9	39
57	Augmented Radiologist Workflow Improves Report Value and Saves Time: A Potential Model for Implementation of Artificial Intelligence. <i>Academic Radiology</i> , 2020, 27, 96-105.	1.3	47
58	Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis. , 2020, 8, e001246.		49
59	The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer. <i>Urologic Clinics of North America</i> , 2020, 47, 457-467.	0.8	7
60	Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management. , 2020, 8, e001019.		13
61	Efficacy and immune-related adverse event associations in avelumab-treated patients. , 2020, 8, e001427.		16
62	14937 Keratoacanthomas associated with anti-TGF- $\beta$ 2 immunotherapy. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB24.	0.6	1
63	A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer. <i>Frontiers in Endocrinology</i> , 2020, 11, 490.	1.5	14
64	Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 3672-3684.	0.8	78
65	Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study. , 2020, 8, e001064.		16
66	Bintrafusp alfa, a bifunctional fusion protein targeting TGF- $\beta$ 2 and PD-L1, in patients with human papillomavirus-associated malignancies. , 2020, 8, e001395.		79
67	Fast Clearance of the SARS-CoV-2 Virus in a Patient Undergoing Vaccine Immunotherapy for Metastatic Chordoma: A Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 603248.	1.3	2
68	Strategies for improving the management of immune-related adverse events. , 2020, 8, e001754.		60
69	643P Evaluating biomarkers in metastatic castration resistant prostate cancer (mCRPC) patients (Pts) treated with enzalutamide (Enza): PSA, circulating tumor cell (CTC) counts, AR-V7 status, PET imaging vs. CT & Tc99 scans. <i>Annals of Oncology</i> , 2020, 31, S527-S528.	0.6	1
70	681P Clinical and immune responses to immunotherapy in biochemically recurrent (non-metastatic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.6	2
71	Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 258-267.e1.	0.9	11
72	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- $\beta$ 2 and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1210-1222.	0.5	119

#	ARTICLE	IF	CITATIONS
73	Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. <i>Journal of the National Cancer Institute</i> , 2020, 112, 562-573.	3.0	45
74	Bintrafusp alfa, a bifunctional fusion protein targeting TGF- $\beta$ 2 and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. , 2020, 8, e000664.		48
75	Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1099-1109.	5.1	59
76	Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis. <i>JAMA Network Open</i> , 2020, 3, e200032.	2.8	17
77	A case report of multiple primary prostate tumors with differential drug sensitivity. <i>Nature Communications</i> , 2020, 11, 837.	5.8	28
78	Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors. <i>Oncologist</i> , 2020, 25, 560.	1.9	17
79	Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure. <i>Annals of Oncology</i> , 2020, 31, 369-376.	0.6	17
80	Dual targeting of TGF- $\beta$ 2 and PD-L1 via a bifunctional anti-PD-L1/TGF- $\beta$ 2RII agent: status of preclinical and clinical advances. , 2020, 8, e000433.		166
81	Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management. <i>Oncologist</i> , 2020, 25, 290-300.	1.9	51
82	Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. , 2020, 8, e000398.		125
83	Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer. , 2020, 8, e000655.		41
84	Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment. <i>Journal of Nuclear Medicine</i> , 2020, 61, 552-562.	2.8	10
85	Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. , 2020, 8, e000878.		63
86	Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 601452.	1.3	1
87	Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 581801.	1.3	11
88	Deep Small Bowel Segmentation with Cylindrical Topological Constraints. <i>Lecture Notes in Computer Science</i> , 2020, 12264, 207-215.	1.0	14
89	456€...Impact of angiotensin II pathway inhibition on tumor response to anti PD(L)1 based therapy. , 2020, , .		1
90	A randomized, double-blind, phase II clinical trial of GI-6301 (yeast-brachyury vaccine) versus placebo in combination with standard of care definitive radiotherapy in locally advanced, unresectable, chordoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11527-11527.	0.8	8

#	ARTICLE	IF	CITATIONS
91	Two-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF- $\beta$ 2 and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, 9558-9558.	0.8	7
92	PSA progression compared to radiographic or clinical progression in metastatic castration-resistant prostate cancer patients treated with enzalutamide.. Journal of Clinical Oncology, 2020, 38, 105-105.	0.8	6
93	Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells. ELife, 2020, 9, .	2.8	32
94	Abstract OT1-08-01: A phase Ib trial of sequential combinations of BN-brachyury, entinostat, ado-trastuzumab emtansine (T-DM1) and bintrafusp alfa (M7824) in advanced stage breast cancer (BrEAsT). Cancer Research, 2020, 80, OT1-08-01-OT1-08-01.	0.4	2
95	A tale of lineage plasticity: Intense neoadjuvant testosterone lowering therapy in localized prostate cancer (PCa) harboring high-risk genomic signatures.. Journal of Clinical Oncology, 2020, 38, 368-368.	0.8	0
96	Evaluating biomarkers in metastatic castration-resistant prostate cancer patients treated with enzalutamide: PSA, circulating tumor cell counts, AR-V7 status and radiographic progression.. Journal of Clinical Oncology, 2020, 38, e17569-e17569.	0.8	0
97	Artificial intelligence assisted bone lesion detection and classification in computed tomography scans of prostate cancer patients.. Journal of Clinical Oncology, 2020, 38, e17567-e17567.	0.8	1
98	Spatial analysis of tumor immune microenvironment (TIME) in patients treated with Bintrafusp alfa.. Journal of Clinical Oncology, 2020, 38, 3070-3070.	0.8	0
99	Bicalutamide with or without metformin for biochemical recurrence in prostate cancer patients (BIMET-1).. Journal of Clinical Oncology, 2020, 38, 85-85.	0.8	0
100	The effect of deep AR suppression with enzalutamide or apalutamide on endogenous glucocorticoids: Implications for adverse effects and development of combination therapies.. Journal of Clinical Oncology, 2020, 38, 17-17.	0.8	0
101	SUN-739 Next Generation AR Antagonists Increase Systemic Active Glucocorticoid Exposure by Altering Glucocorticoid Metabolism. Journal of the Endocrine Society, 2020, 4, .	0.1	0
102	Acquired Coagulopathy With Immune Checkpoint Inhibitors: An Underrecognized Association Between Inflammation and Coagulation. JTO Clinical and Research Reports, 2020, 1, 100049.	0.6	5
103	375â€¦Expansion of HPV-16 specific T cells in patients with HPV-related cancers treated with bintrafusp alfa. , 2020, , .		0
104	296â€¦Immune correlates of clinical response to Avelumab in patients with advanced thymic epithelial tumors. , 2020, , .		0
105	265â€¦Phase 1b study of avelumab + M9241 (NHS-IL12) in patients with advanced solid tumors: interim analysis results from a urothelial carcinoma (UC) dose-expansion cohort. , 2020, , .		0
106	First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors. Clinical Cancer Research, 2019, 25, 99-109.	3.2	116
107	The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. Clinical Cancer Research, 2019, 25, 6916-6924.	3.2	200
108	Successful 5-fluorouracil (5-FU) infusion re-challenge in a metastatic colorectal cancer patient with coronary artery disease who experienced symptoms consistent with coronary vasospasm during first 5-FU infusion. Journal of Gastrointestinal Oncology, 2019, 10, 1010-1014.	0.6	7

#	ARTICLE	IF	CITATIONS
109	Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial. , 2019, 7, 275.		48
110	If we build it they will come: targeting the immune response to breast cancer. Npj Breast Cancer, 2019, 5, 37.	2.3	132
111	Radium-223 mechanism of action: implications for use in treatment combinations. Nature Reviews Urology, 2019, 16, 745-756.	1.9	71
112	Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. , 2019, 7, 269.		94
113	Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. , 2019, 7, 240.		162
114	Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer. JAMA Oncology, 2019, 5, 393.	3.4	303
115	Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report. BMC Cancer, 2019, 19, 539.	1.1	12
116	A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules. Clinical Cancer Research, 2019, 25, 4933-4944.	3.2	45
117	Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis. , 2019, 7, 119.		35
118	Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab. Molecular Imaging, 2019, 18, 153601211982998.	0.7	55
119	mpMRI preoperative staging in men treated with antiandrogen and androgen deprivation therapy before robotic prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 352.e25-352.e30.	0.8	4
120	A Case of Anti-“PD-L1-associated Remitting Seronegative Symmetric Synovitis With Pitting Edema. Clinical Genitourinary Cancer, 2019, 17, e549-e552.	0.9	5
121	Current Landscape of Immunotherapy in Breast Cancer. JAMA Oncology, 2019, 5, 1205.	3.4	260
122	Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2019, 37, 1051-1061.	0.8	174
123	Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. Oncologist, 2019, 24, 1259-1269.	1.9	127
124	Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. Annals of the Rheumatic Diseases, 2019, 78, 150-152.	0.5	97
125	Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma. JAMA Oncology, 2019, 5, 351.	3.4	127
126	Product review: avelumab, an anti-PD-L1 antibody. Human Vaccines and Immunotherapeutics, 2019, 15, 891-908.	1.4	50



#	ARTICLE	IF	CITATIONS
127	Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial. , 2019, 7, 12.		67
128	Finding an Immunologic Beachhead in the Prostate Cancer Microenvironment. Journal of the National Cancer Institute, 2019, 111, 219-220.	3.0	10
129	Abstract CT075: Phase I evaluation of M7824, a bifunctional fusion protein targeting TGF- $\beta$ 2 and PD-L1, in patients with human papillomavirus (HPV)-associated malignancies. , 2019, , .		13
130	Clinical efficacy of abiraterone and enzalutamide metastatic castration sensitive prostate cancer patients who progressed rapidly on docetaxel with a genomic analysis.. Journal of Clinical Oncology, 2019, 37, e16536-e16536.	0.8	0
131	Phase I trial of a modified vaccinia ankara (MVA) priming vaccine followed by a fowlpox virus (FPV) boosting vaccine modified to express brachyury and costimulatory molecules in advanced solid tumors.. Journal of Clinical Oncology, 2019, 37, 2640-2640.	0.8	0
132	Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. Cancer, 2018, 124, 2010-2017.	2.0	81
133	Anti-“PD-L1 Treatment Induced Central Diabetes Insipidus. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 365-369.	1.8	88
134	Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF $\beta$ 2, in Advanced Solid Tumors. Clinical Cancer Research, 2018, 24, 1287-1295.	3.2	304
135	Morphological changes induced by intraprostatic PSA-based vaccine in prostate cancer biopsies (phase I) Tj ETQq1 1,0,784314,rgBT /O 1,1		
136	A Prospective Comparison of <sup>18</sup> F-Sodium Fluoride PET/CT and PSMA-Targeted <sup>18</sup> F-DCFBC PET/CT in Metastatic Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 1665-1671.	2.8	40
137	Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncology, The, 2018, 19, 51-64.	5.1	491
138	Vaccines as an Integral Component of Cancer Immunotherapy. JAMA - Journal of the American Medical Association, 2018, 320, 2195.	3.8	27
139	A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study. European Urology Focus, 2018, 4, 636-638.	1.6	16
140	Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report. , 2018, 6, 150.		27
141	Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. , 2018, 6, 141.		214
142	Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. , 2018, 6, 111.		122
143	Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer. , 2018, 6, 91.		51
144	Avelumab: is it time to get excited?. Expert Review of Anticancer Therapy, 2018, 18, 815-821.	1.1	6

#	ARTICLE	IF	CITATIONS
145	Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy. Expert Review of Vaccines, 2018, 17, 697-705.	2.0	38
146	Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. , 2018, 6, 35.		172
147	White paper on microbial anti-cancer therapy and prevention. , 2018, 6, 78.		108
148	Pembrolizumab: patient selection or immune intensification?. Nature Reviews Urology, 2018, 15, 593-594.	1.9	0
149	Selection of the recommended phase 2 dose (RP2D) for M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF- $\beta$ 2 and PD-L1.. Journal of Clinical Oncology, 2018, 36, 2566-2566.	0.8	9
150	Safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF- $\beta$ 2, in patients with HPV associated cancers.. Journal of Clinical Oncology, 2018, 36, 3007-3007.	0.8	36
151	Association of efficacy and adverse events of special interest of avelumab in the JAVELIN solid tumor and JAVELIN Merkel 200 trials.. Journal of Clinical Oncology, 2018, 36, 3057-3057.	0.8	1
152	Effect of rilimogene galvacirepvec/rilimogene glafolivec on intra/peritumoral immune infiltrate in patients with localized prostate cancer undergoing radical prostatectomy.. Journal of Clinical Oncology, 2018, 36, 5083-5083.	0.8	2
153	Avelumab (anti- $\beta$ PD-L1) in patients with platinum-treated advanced NSCLC: 2.5-year follow-up from the JAVELIN Solid Tumor trial.. Journal of Clinical Oncology, 2018, 36, 9090-9090.	0.8	7
154	A sequential cohort study of combination immunotherapy with BN-brachyury vaccine, M7824, ALT-803 and epacadostat in metastatic castration-resistant prostate cancer (mCRPC) (QuEST1).. Journal of Clinical Oncology, 2018, 36, TPS3130-TPS3130.	0.8	1
155	M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF- $\beta$ 2, in patients with heavily pretreated CRC: Preliminary results from a phase I trial.. Journal of Clinical Oncology, 2018, 36, 764-764.	0.8	13
156	Avelumab in patients with previously treated mesothelioma: Updated phase 1b results from the JAVELIN Solid Tumor trial.. Journal of Clinical Oncology, 2018, 36, 166-166.	0.8	5
157	Avelumab in patients with previously treated metastatic melanoma: Phase 1b results from the JAVELIN Solid Tumor trial.. Journal of Clinical Oncology, 2018, 36, 191-191.	0.8	3
158	A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population.. Journal of Clinical Oncology, 2018, 36, 163-163.	0.8	35
159	Immunotherapy for biochemically recurrent prostate cancer.. Journal of Clinical Oncology, 2018, 36, 215-215.	0.8	5
160	Immunological and genomic correlates of response to anti-PD1 checkpoint therapy in mismatch proficient and deficient patients with metastasized castration resistant prostate cancer.. Journal of Clinical Oncology, 2018, 36, 248-248.	0.8	5
161	M7824: A promising new strategy to combat cancer immune evasion. Oncoscience, 2018, 5, 269-270.	0.9	21
162	A comparison of prostate cancer bone metastases on 18F-Sodium Fluoride and Prostate Specific Membrane Antigen (18F-PSMA) PET/CT: Discordant uptake in the same lesion. Oncotarget, 2018, 9, 37676-37688.	0.8	13

#	ARTICLE	IF	CITATIONS
163	Perspectives on the clinical development of immunotherapy in prostate cancer. Asian Journal of Andrology, 2018, 20, 253.	0.8	13
164	Validation of a software-based clinical trial matching platform for oncology using comprehensive clinical information.. Journal of Clinical Oncology, 2018, 36, e18589-e18589.	0.8	0
165	Phase 1b results of avelumab in patients (pts) with previously treated metastatic melanoma enrolled in the JAVELIN Solid Tumor trial, including updated subgroup analyses.. Journal of Clinical Oncology, 2018, 36, e21531-e21531.	0.8	0
166	Abstract 3671: Phenotypic heterogeneity within prostate cancer bone metastases measured by 18F-DCFBP PET/CT and 18F-NaF PET/CT. , 2018, , .		0
167	Abstract IA24: Making immunotherapy work in prostate cancer. , 2018, , .		0
168	A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma. Clinical Genitourinary Cancer, 2017, 15, 77-85.	0.9	40
169	Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody. , 2017, 5, 20.		78
170	ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody. International Journal of Cancer, 2017, 141, 583-593.	2.3	37
171	PSA. , 2017, , 451-458.		0
172	Better VISTAs ahead? Potential and pitfalls of immunotherapy. Nature Reviews Urology, 2017, 14, 455-456.	1.9	9
173	Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncology, The, 2017, 18, 599-610.	5.1	257
174	Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncology, The, 2017, 18, 587-598.	5.1	261
175	Editorial: Local Immunotherapy: A Way to Convert Tumors From "Cold" to "Hot". Journal of the National Cancer Institute, 2017, 109, .	3.0	15
176	MP15-10 IMMUNOLOGIC RESPONSE TO A THERAPEUTIC CANCER VACCINE (PANVAC): INITIAL RESULTS FROM A RANDOMIZED PHASE 2 CLINICAL TRIAL. Journal of Urology, 2017, 197, .	0.2	4
177	A novel bifunctional anti-PD-L1/TGF- $\beta$ 2 Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells. OncoImmunology, 2017, 6, e1349589.	2.1	137
178	Combining immunotherapies for the treatment of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 694-700.	0.8	36
179	Prostate cancer immunotherapy: the path forward. Current Opinion in Supportive and Palliative Care, 2017, 11, 225-230.	0.5	8
180	Immunotherapy biomarkers 2016: overcoming the barriers. , 2017, 5, 29.		21

#	ARTICLE	IF	CITATIONS
181	Immunotherapy of Prostate Cancer: Facts and Hopes. <i>Clinical Cancer Research</i> , 2017, 23, 6764-6770.	3.2	173
182	Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 124-125.	0.8	56
183	Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	139
184	Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016. , 2017, 5, 55.		5
185	Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2117-2124.	0.8	538
186	Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury. <i>Clinical Cancer Research</i> , 2017, 23, 6833-6845.	3.2	51
187	Preliminary results from a phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF- $\beta$ 2, in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3006-3006.	0.8	21
188	Safety profile of avelumab in patients with advanced solid tumors: A JAVELIN pooled analysis of phase 1 and 2 data.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3059-3059.	0.8	5
189	Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5026-5026.	0.8	13
190	Avelumab in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5037-5037.	0.8	2
191	Exposure-response and PD-L1 expression analysis of second-line avelumab in patients with advanced NSCLC: Data from the JAVELIN Solid Tumor trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9086-9086.	0.8	11
192	Avelumab for the treatment of metastatic Merkel cell carcinoma. <i>Drugs of Today</i> , 2017, 53, 377.	0.7	6
193	Analyses of functions of an anti-PD-L1/TGF- $\beta$ 2 bispecific fusion protein (M7824). <i>Oncotarget</i> , 2017, 8, 75217-75231.	0.8	44
194	Checkpoint and PARP inhibitors, for whom and when. <i>Oncotarget</i> , 2017, 8, 95036-95037.	0.8	9
195	Avelumab demonstrates promise in advanced NSCLC. <i>Oncotarget</i> , 2017, 8, 102767-102768.	0.8	3
196	Infusion-related reactions with administration of avelumab: mild and manageable side effects. <i>Translational Cancer Research</i> , 2017, 6, S1296-S1298.	0.4	4
197	Abstract LB-059: Neoadjuvant immunotherapy with androgen deprivation therapy (ADT) prior to radiation in prostate cancer: Impact on multiparametric prostate MRI and immune responses. , 2017, , .		0
198	Abstract CT080: Pharmacokinetic and pharmacodynamic analysis of M7824, a dual anti-PD-L1 and TGF- $\beta$ 2 TRAP molecule, in the first-in-human phase I dose escalation study. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
199	Abstract CT058: A phase 2 open-label study to evaluate the efficacy and safety of VT-464 in patients with androgen receptor positive triple-negative breast cancer patients, and men with ER positive breast cancer. , 2017, , .		0
200	The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells. <i>Oncotarget</i> , 2016, 7, 37762-37772.	0.8	96
201	Predicting clinical outcomes in chordoma patients receiving immunotherapy: a comparison between volumetric segmentation and RECIST. <i>BMC Cancer</i> , 2016, 16, 672.	1.1	14
202	The evolving role of immunotherapy in prostate cancer. <i>Current Opinion in Oncology</i> , 2016, 28, 232-240.	1.1	10
203	TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer. <i>Oncolimmunology</i> , 2016, 5, e1197459.	2.1	24
204	Cognitive testing of tobacco use items for administration to patients with cancer and cancer survivors in clinical research. <i>Cancer</i> , 2016, 122, 1728-1734.	2.0	26
205	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. , 2016, 4, 92.		31
206	Immunotherapy in genitourinary malignancies. <i>Current Opinion in Urology</i> , 2016, 26, 501-507.	0.9	6
207	Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm. <i>Oncolimmunology</i> , 2016, 5, e1107698.	2.1	28
208	Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 895-901.	1.4	20
209	Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2219-2231.	1.4	49
210	Developing immunotherapy strategies in the treatment of prostate cancer. <i>Asian Journal of Urology</i> , 2016, 3, 278-285.	0.5	11
211	Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. <i>Cancer Immunology Research</i> , 2016, 4, 755-765.	1.6	36
212	Radium-223 in prostate cancer: emitting the right signals. <i>Lancet Oncology</i> , The, 2016, 17, 1186-1187.	5.1	1
213	Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types. <i>Journal of Circulating Biomarkers</i> , 2016, 5, 5.	0.8	50
214	Resources Required for Semi-Automatic Volumetric Measurements in Metastatic Chordoma: Is Potentially Improved Tumor Burden Assessment Worth the Time Burden?. <i>Journal of Digital Imaging</i> , 2016, 29, 357-364.	1.6	11
215	Phase <sc>II</sc> trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2016, 118, 590-597.	1.3	23
216	Prospective Study Evaluating Na<sup>18</sup>F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 886-892.	2.8	78

#	ARTICLE	IF	CITATIONS
217	Prospects for the future of prostate cancer vaccines. Expert Review of Vaccines, 2016, 15, 271-274.	2.0	5
218	Abstract 4901: Short-course enzalutamide reveals immune activating properties in patients with biochemically recurrent prostate cancer. Cancer Research, 2016, 76, 4901-4901.	0.4	4
219	Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced cancer: Safety data from 1300 patients enrolled in the phase 1b JAVELIN Solid Tumor trial.. Journal of Clinical Oncology, 2016, 34, 3055-3055.	0.8	10
220	Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression.. Journal of Clinical Oncology, 2016, 34, 4514-4514.	0.8	18
221	Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced adrenocortical carcinoma from the JAVELIN solid tumor phase 1b trial: Safety and clinical activity.. Journal of Clinical Oncology, 2016, 34, 4516-4516.	0.8	5
222	A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2016, 34, 4534-4534.	0.8	8
223	Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase 1b trial: Safety and clinical activity.. Journal of Clinical Oncology, 2016, 34, 5533-5533.	0.8	117
224	Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase 1b trial: Safety, clinical activity, and PD-L1 expression.. Journal of Clinical Oncology, 2016, 34, 8503-8503.	0.8	43
225	Short course enzalutamide monotherapy in biochemically recurrent prostate cancer: Clinical and immunologic impact.. Journal of Clinical Oncology, 2016, 34, e16619-e16619.	0.8	1
226	Safety and clinical activity of anti-programmed death-ligand 1 (PD-L1) antibody (ab) avelumab (MSB0010718C) in advanced thymic epithelial tumors (TETs).. Journal of Clinical Oncology, 2016, 34, e20106-e20106.	0.8	7
227	Clinical and immunologic impact of short course enzalutamide without androgen deprivation therapy for biochemically recurrent prostate cancer.. Journal of Clinical Oncology, 2016, 34, 214-214.	0.8	4
228	Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase 1b trial.. Journal of Clinical Oncology, 2016, 34, 367-367.	0.8	26
229	Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial. Oncotarget, 2016, 7, 69014-69023.	0.8	38
230	Comparison of survival of African-American (AA) patients (pts) in docetaxel (D)-based combination therapies in metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2016, 34, 272-272.	0.8	0
231	An analysis of sodium 18f-fluoride PET/CT and prostate specific antigen (PSA) changes in men with metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2016, 34, 203-203.	0.8	0
232	An analysis of sodium 18F-fluoride PET/CT and prostate specific antigen (PSA) changes in men with metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2016, 34, e23149-e23149.	0.8	0
233	Abstract CT132: Safety of avelumab (MSB0010718C), an anti-PD-L1 antibody: updated analysis from the phase 1b JAVELIN Solid Tumor trial. , 2016, , .		0
234	Abstract 2048: Pharmacodynamic biomarker studies of TRC105 anti-endoglin (CD105) antibody revealed anti-angiogenic activity associated with CD105 depletion. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
235	Abstract 1406: Analysis of immune responses as a consequence of androgen deprivation therapy in patients with biochemical progression of prostate cancer. , 2016, , .		0
236	Personalized peptide vaccine in prostate cancer: capitalizing on existing immunity. Translational Cancer Research, 2016, 5, S1333-S1335.	0.4	1
237	Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-“PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunology Research, 2015, 3, 1148-1157.	1.6	391
238	Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer. JAMA Oncology, 2015, 1, 1087.	3.4	80
239	A National Multicenter Phase 2 Study of Prostate-specific Antigen (PSA) Pox Virus Vaccine with Sequential Androgen Ablation Therapy in Patients with PSA Progression: ECOG 9802. European Urology, 2015, 68, 365-371.	0.9	43
240	Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (Gl-6301) Targeting the Transcription Factor Brachyury. Cancer Immunology Research, 2015, 3, 1248-1256.	1.6	118
241	Moving the goal posts in prostate cancer trials. Lancet Oncology, The, 2015, 16, 247-249.	5.1	3
242	Effect of TLR Agonists on the Differentiation and Function of Human Monocytic Myeloid-Derived Suppressor Cells. Journal of Immunology, 2015, 194, 4215-4221.	0.4	60
243	The impact of leukapheresis on immune-cell number and function in patients with advanced cancer. Cancer Immunology, Immunotherapy, 2015, 64, 1429-1435.	2.0	2
244	Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809). Human Vaccines and Immunotherapeutics, 2015, 11, 2469-2474.	1.4	26
245	A phase I study of TRC105 anti-“endoglin (CD105) antibody in metastatic castration-resistant prostate cancer. BJU International, 2015, 116, 546-555.	1.3	55
246	Abstract 1586: Recovery and characterization of circulating tumor cells (CTCs) in cryopreserved metastatic castrate-resistant prostate cancer (mCRPC) patient samples. , 2015, , .		1
247	Antibody dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody, avelumab (MSB0010718C), on human tumor cells.. Journal of Clinical Oncology, 2015, 33, 3038-3038.	0.8	2
248	Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors: assessment of safety and tolerability in a phase I, open-label expansion study.. Journal of Clinical Oncology, 2015, 33, 3044-3044.	0.8	25
249	Pharmacokinetic profile and receptor occupancy of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in a phase I, open-label, dose escalation trial in patients with advanced solid tumors.. Journal of Clinical Oncology, 2015, 33, 3055-3055.	0.8	19
250	Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial.. Journal of Clinical Oncology, 2015, 33, 5509-5509.	0.8	79
251	Prospect: A randomized double-blind phase 3 efficacy study of PROSTVAC-VF immunotherapy in men with asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2015, 33, TPS5081-TPS5081.	0.8	5
252	Impact of standard chemotherapy on peripheral blood immune cell subsets in metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, 597-597.	0.8	1

#	ARTICLE	IF	CITATIONS
253	Combining active immunotherapy and immune checkpoint inhibitors in prostate cancer.. Journal of Clinical Oncology, 2015, 33, 172-172.	0.8	9
254	Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2015, 33, 235-235.	0.8	1
255	ABO blood type correlates with survival on prostate cancer vaccine therapy. Oncotarget, 2015, 6, 32244-32256.	0.8	18
256	The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic. Oncotarget, 2015, 6, 31344-31359.	0.8	32
257	Association of NaF PET/CT findings with PSA and alkaline phosphatase in untreated castration-sensitive prostate cancer.. Journal of Clinical Oncology, 2015, 33, 122-122.	0.8	0
258	Ferumoxytol enhanced MRI for lymph node staging in prostate cancer.. Journal of Clinical Oncology, 2015, 33, 208-208.	0.8	1
259	Phase I expansion cohort trial to investigate the safety and clinical activity of avelumab (MSB0010718C) in patients with metastatic or locally advanced solid tumors.. Journal of Clinical Oncology, 2015, 33, TPS3101-TPS3101.	0.8	0
260	Combining active immunotherapy and immune checkpoint inhibitors in prostate cancer.. Journal of Clinical Oncology, 2015, 33, e14008-e14008.	0.8	2
261	Evaluation of a new circulating tumor cell (CTC) platform to predict response and survival in metastatic urothelial carcinoma (UC) patients receiving cabozantinib (cabo).. Journal of Clinical Oncology, 2015, 33, e15501-e15501.	0.8	0
262	The impact of age on sipuleucel-T-induced immune responses.. Journal of Clinical Oncology, 2015, 33, e16009-e16009.	0.8	0
263	Overcoming resistance mechanisms in a study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2015, 33, e16032-e16032.	0.8	0
264	Abstract B100: Panvac-F and Panvac-V: Phase I study of intratumoral and systemic vaccination. , 2015, , .		0
265	Abstract 1316: Evaluation of immune cell subsets of cancer patients treated with a fully human IgG1 anti-PD-L1 MAb (MSB0010718C) capable of mediating ADCC of human tumor cells. Cancer Research, 2015, 75, 1316-1316.	0.4	1
266	Abstract 366: A novel transcript variant of androgen receptor identified in circulating tumor cells from castration-resistant prostate cancer patients as a potentially prognostic biomarker. , 2015, , .		0
267	Abstract CT222: Ferumoxytol enhanced MRI for lymph node staging in genitourinary cancers. , 2015, , .		0
268	Adding fuel to the fire: Immunogenic intensification. Human Vaccines and Immunotherapeutics, 2014, 10, 3306-3312.	1.4	4
269	Exploiting Synergy: Immune-Based Combinations in the Treatment of Prostate Cancer. Frontiers in Oncology, 2014, 4, 351.	1.3	15
270	Pan-Bcl-2 Inhibitor, GX15-070 (Obatoclax), Decreases Human T Regulatory Lymphocytes while Preserving Effector T Lymphocytes: A Rationale for Its Use in Combination Immunotherapy. Journal of Immunology, 2014, 192, 2622-2633.	0.4	25



#	ARTICLE	IF	CITATIONS
271	(R)Evolutionary Therapy: The Potential of Immunotherapy to Fulfill the Promise of Personalized Cancer Treatment. <i>Journal of the National Cancer Institute</i> , 2014, 107, dju347-dju347.	3.0	4
272	Therapeutic Cancer Vaccines. <i>Advances in Cancer Research</i> , 2014, 121, 67-124.	1.9	68
273	The Use of T Cell Costimulation to Enhance the Immunogenicity of Tumors. , 2014, , 315-334.		0
274	Poxviral-based vaccine elicits immunologic responses in prostate cancer patients. <i>Oncolimmunology</i> , 2014, 3, e28611.	2.1	14
275	Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 225-234.	2.0	86
276	Identification and characterization of agonist epitopes of the MUC1-C oncoprotein. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 161-174.	2.0	23
277	Therapeutic Cancer Vaccines: An Emerging Approach to Cancer Treatment. <i>Cancer Drug Discovery and Development</i> , 2014, , 553-568.	0.2	0
278	Humoral response to a viral glycan correlates with survival on PROSTVAC-VF. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E1749-58.	3.3	41
279	Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets. <i>International Journal of Cancer</i> , 2014, 135, 862-870.	2.3	5
280	Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances. <i>Therapeutic Advances in Vaccines</i> , 2014, 2, 137-148.	2.7	19
281	Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1769-1781.	1.4	4
282	Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer. <i>Cancer Immunology Research</i> , 2014, 2, 133-141.	1.6	115
283	Nivolumab: Promising Survival Signal Coupled With Limited Toxicity Raises Expectations. <i>Journal of Clinical Oncology</i> , 2014, 32, 986-988.	0.8	50
284	A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 407-418.	2.0	82
285	TRICOM Poxviral-Based Vaccines for the Treatment of Cancer. , 2014, , 291-327.		1
286	Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3064-3064.	0.8	31
287	NCI experience using yeast-brachyury vaccine (GI-6301) in patients (pts) with advanced chordoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3081-3081.	0.8	6
288	Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4501-4501.	0.8	28

#	ARTICLE	IF	CITATIONS
289	A phase I study of a yeast-based therapeutic cancer vaccine, GI-6301, targeting brachyury in patients with metastatic carcinoma.. Journal of Clinical Oncology, 2014, 32, e14026-e14026.	0.8	2
290	A randomized, prospective, phase II study to determine the efficacy of BCG given in combination with panvac versus BCG alone in adults with high grade non-muscle invasive bladder cancer who failed at least one induction course of BCG.. Journal of Clinical Oncology, 2014, 32, TPS4590-TPS4590.	0.8	6
291	A phase I study of the multikinase inhibitor cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2014, 32, 108-108.	0.8	2
292	A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2014, 32, 307-307.	0.8	6
293	Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer. Translational Lung Cancer Research, 2014, 3, 403-5.	1.3	21
294	Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications. Asian Journal of Andrology, 2014, 16, 364.	0.8	15
295	Immune impact induced by PSA-tricom, a therapeutic vaccine for prostate cancer.. Journal of Clinical Oncology, 2014, 32, 245-245.	0.8	0
296	A safety study of trebananib (AMG 386) and abiraterone in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2014, 32, 218-218.	0.8	0
297	ARv567es as detected in circulating tumor cells: An innovative methodology for the detection of a prognostic and therapeutic biomarker.. Journal of Clinical Oncology, 2014, 32, 112-112.	0.8	0
298	A safety study of trebananib (AMG 386) and abiraterone in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2014, 32, 5074-5074.	0.8	0
299	A phase I study of gemcitabine, carboplatin, and lenalidomide for treatment of patients with advanced/metastatic urothelial carcinoma (UC) and other solid tumors.. Journal of Clinical Oncology, 2014, 32, e15527-e15527.	0.8	0
300	A safety study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2014, 32, 5072-5072.	0.8	0
301	Abstract 2544: Identification of immune signatures predicting for clinical outcome measured by flow-cytometry and immunogenetic analysis of PBMCs from breast cancer patients treated with docetaxel alone or docetaxel plus vaccine. , 2014, , .		0
302	Abstract 2546: Analysis of immune cell subsets in a multidrug therapeutic regimen for patients with metastatic castration-resistant prostate cancer. , 2014, , .		0
303	Abstract 628: Pan-Bcl-2 inhibitor, GX15-070 (Obatoclox), decreases human T regulatory lymphocytes while preserving effector T Lymphocytes: A rationale for its use in combination immunotherapy. , 2014, , .		0
304	Abstract 5012: A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: Immune correlates. , 2014, , .		0
305	Abstract 4815: A novel AR splice variant identified in circulating tumor cells from castration-resistant prostate cancer patient blood as a potentially prognostic biomarker. , 2014, , .		0
306	Phase II Study of Satraplatin and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Pharmacogenetic Assessment of Outcome and Toxicity. Clinical Genitourinary Cancer, 2013, 11, 229-237.	0.9	23

#	ARTICLE	IF	CITATIONS
307	Recombinant TRICOM-based Therapeutic Cancer Vaccines. , 2013, , 309-331.		1
308	Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1521-1531.	2.0	38
309	Serum Antibodies to Blood Group A Predict Survival on PROSTVAC-VF. <i>Clinical Cancer Research</i> , 2013, 19, 1290-1299.	3.2	50
310	Dramatic and Prolonged PSA Response After Retreatment With a PSA Vaccine. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 362-364.	0.9	3
311	970 PROSPECT: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 EFFICACY TRIAL OF PROSTVAC-VF IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. <i>Journal of Urology</i> , 2013, 189, .	0.2	1
312	Combining Vaccines with Therapies that Render Tumor Cells more Susceptible to Immune Mediated Killing. , 2013, , 621-642.		0
313	Impact of androgen deprivation therapy on the thymus and the production of na <sup>+</sup> ve T-cells. , 2013, 1, .		1
314	Ipilimumab in prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 303-313.	1.4	7
315	Demystifying Immunotherapy in Prostate Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2013, 19, 50-58.	1.0	20
316	Effect of Talactoferrin Alfa on the Immune System in Adults With Non <sup>+</sup> small Cell Lung Cancer. <i>Oncologist</i> , 2013, 18, 821-822.	1.9	9
317	Phase <sup>II</sup> clinical trial of cediranib in patients with metastatic castration <sup>+</sup> resistant prostate cancer. <i>BJU International</i> , 2013, 111, 1269-1280.	1.3	40
318	Up <sup>+</sup> regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration <sup>+</sup> resistant prostate cancer. <i>International Journal of Cancer</i> , 2013, 133, 373-382.	2.3	31
319	Soluble CD27-Pool in Humans May Contribute to T Cell Activation and Tumor Immunity. <i>Journal of Immunology</i> , 2013, 190, 6250-6258.	0.4	59
320	Therapeutic vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 219-221.	1.4	42
321	The role of soluble CD40L in immunosuppression. <i>Oncolmmunology</i> , 2013, 2, e22546.	2.1	24
322	Intermediate efficacy end points to assess modern therapies. <i>Nature Reviews Urology</i> , 2013, 10, 686-687.	1.9	1
323	Effects of conventional therapeutic interventions on the number and function of regulatory T cells. <i>Oncolmmunology</i> , 2013, 2, e27025.	2.1	148
324	Novel immunotherapeutic agents for castration-resistant prostate cancer: update from clinical trials. <i>Clinical Investigation</i> , 2013, 3, 651-663.	0.0	0

#	ARTICLE	IF	CITATIONS
325	Therapeutic Vaccines and Immunotherapy in Castration-Resistant Prostate Cancer: Current Progress and Clinical Applications. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e166-e170.	1.8	13
326	Calculation of an immunoscore based on extensive flow cytometry analysis of PBMCs from metastatic breast cancer patients treated with docetaxel alone or in combination with vaccine.. Journal of Clinical Oncology, 2013, 31, 31-31.	0.8	1
327	A phase II randomized clinical trial of samarium-153 EDTMP (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel.. Journal of Clinical Oncology, 2013, 31, 102-102.	0.8	14
328	Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC).. Journal of Clinical Oncology, 2013, 31, 314-314.	0.8	6
329	Effect of PSA-tricom, a pox-viral vaccine in prostate cancer (PCa), on tumor growth rates within 80 days after initiation in nonmetastatic PCa.. Journal of Clinical Oncology, 2013, 31, 57-57.	0.8	5
330	Issues in Pre-clinical Models, Clinical Trial Design and Analytical Considerations in Developing and Evaluating Novel Cancer Immunotherapies. , 2013, , 455-474.		0
331	PSA. , 2013, , 1-8.		0
332	Abstract IA13: Phase I trial of targeted therapy with PSA-TRICOM vaccine (V) and ipilimumab (ipi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. , 2013, , .		0
333	Safety profile of poxviral vaccines: NCI experience.. Journal of Clinical Oncology, 2013, 31, 85-85.	0.8	0
334	Feasibility of continuing docetaxel-based therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) that experience hypersensitivity reactions (HSR).. Journal of Clinical Oncology, 2013, 31, 132-132.	0.8	0
335	Use of supportive measures to improve outcome and decrease toxicity in docetaxel-based antiangiogenesis combinations.. Journal of Clinical Oncology, 2013, 31, 128-128.	0.8	1
336	Preliminary results of a prospective study of 18F-NAF PET/CT in prostate cancer.. Journal of Clinical Oncology, 2013, 31, 103-103.	0.8	1
337	Abstract 4571: Autologous TARP peptide vaccination is associated with slowing in PSA velocity and a decrease in tumor growth rate in patients with Stage D0 prostate cancer.. , 2013, , .		0
338	Therapeutic Vaccines and Immunotherapy in Castration-Resistant Prostate Cancer: Current Progress and Clinical Applications. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e166-e170.	1.8	4
339	Safety profile of recombinant poxviral TRICOM vaccines.. Journal of Clinical Oncology, 2013, 31, e16036-e16036.	0.8	0
340	Immunotherapy: Shifting the Balance of Cell-Mediated Immunity and Suppression in Human Prostate Cancer. Cancers, 2012, 4, 1333-1348.	1.7	4
341	Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity. Oncolmmunology, 2012, 1, 1167-1168.	2.1	19
342	Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy. Prostate Cancer and Prostatic Diseases, 2012, 15, 289-295.	2.0	12

#	ARTICLE	IF	CITATIONS
343	The Kinetics and Reproducibility of <sup>18</sup> F-Sodium Fluoride for Oncology Using Current PET Camera Technology. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1175-1184.	2.8	71
344	Re: Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1106-1106.	3.0	13
345	Strategies for Optimizing the Clinical Impact of Immunotherapeutic Agents Such as Sipuleucel-T in Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1505-1512.	2.3	11
346	Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. <i>Blood</i> , 2012, 120, 3030-3038.	0.6	107
347	Toward an off-the-shelf vaccine for B-cell malignancies. <i>Blood</i> , 2012, 120, 1539-1540.	0.6	2
348	Combining radiation and therapeutic cancer vaccines: a synergistic approach. <i>Breast Cancer Management</i> , 2012, 1, 325-335.	0.2	0
349	Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. <i>Lancet Oncology</i> , The, 2012, 13, 501-508.	5.1	333
350	Progress in prostate cancer imaging. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 938-939.	0.8	4
351	Poxviral vectors for cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 463-478.	1.4	35
352	Initial PSA Oscillations Precede Prolonged Stable Disease in a Patient Treated With a Therapeutic Cancer Vaccine. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 43-46.	0.9	3
353	Clinical Evaluation of TRICOM Vector Therapeutic Cancer Vaccines. <i>Seminars in Oncology</i> , 2012, 39, 296-304.	0.8	75
354	Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 109-117.	2.0	34
355	Interim analysis of a phase II randomized clinical trial of samrium-153 (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer after docetaxel.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2526-2526.	0.8	11
356	Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4569-4569.	0.8	3
357	Prospect: A randomized, double-blind, phase III efficacy trial of PROSTVAC.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS4699-TPS4699.	0.8	1
358	Randomized phase II clinical trial to assess MUC1 specific immune response to L-BLP25 vaccine in addition to standard therapy in newly diagnosed high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS4701-TPS4701.	0.8	1
359	A phase I trial of a recombinant CEA yeast-based vaccine targeting CEA-expressing cancers.. <i>Journal of Clinical Oncology</i> , 2012, 30, 458-458.	0.8	2
360	A phase I study of TRC105 (anti-CD105 [endoglin] antibody) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 117-117.	0.8	2

#	ARTICLE	IF	CITATIONS
361	Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2012, 30, 207-207.	0.8	5
362	Abstract PL03-02: Current status of recombinant pox-viral vaccines. , 2012, , .		0
363	Abstract 5404: Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer. , 2012, , .		0
364	Abstract 5378: Phase I trial of EUS-guided intratumoral vaccination with recombinant Panvac-F and systemic Panvac-V in patients with locally advanced pancreatic cancer. , 2012, , .		0
365	Abstract 5379: Combination treatment with Bevacizumab, Lenalidomide, Docetaxel and Prednisone (ART-P) does not impact the immune response in patients with metastatic castration-resistant prostate cancer. , 2012, , .		0
366	A pilot study on the clinical value of 18F-sodium fluoride PET/CT in advanced prostate cancer.. Journal of Clinical Oncology, 2012, 30, 10589-10589.	0.8	1
367	A phase I study of TRC105 (Anti-CD105 [endoglin] antibody) in metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2012, 30, 3043-3043.	0.8	3
368	A pilot trial of a combination of therapeutic vaccines (GI-4000 and GI-6207) as adjunctive therapy with first-line therapy with bevacizumab plus either FOLFOX or FOLFIRI in stage IV patients with newly diagnosed Ras-mutant positive or negative metastatic colorectal cancer.. Journal of Clinical Oncology, 2012, 30, TPS3638-TPS3638.	0.8	0
369	Immunotherapy for Prostate Cancer: Recent Advances, Lessons Learned, and Areas for Further Research. Clinical Cancer Research, 2011, 17, 3884-3891.	3.2	110
370	Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells. Vaccine, 2011, 29, 4992-4999.	1.7	22
371	Impact of Tumour Volume on the Potential Efficacy of Therapeutic Vaccines. Current Oncology, 2011, 18, 150-157.	0.9	90
372	HEPCIDIN, ANAEMIA, AND PROSTATE CANCER. BJU International, 2011, 107, 678-679.	1.3	29
373	Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. Cancer Immunology, Immunotherapy, 2011, 60, 197-206.	2.0	51
374	Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer. Immunotherapy, 2011, 3, 27-31.	1.0	12
375	Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer. Expert Review of Vaccines, 2011, 10, 141-150.	2.0	23
376	A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver. Expert Opinion on Biological Therapy, 2011, 11, 1409-1418.	1.4	24
377	A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer. Clinical Cancer Research, 2011, 17, 7164-7173.	3.2	111
378	Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy. Clinical Cancer Research, 2011, 17, 907-917.	3.2	224

#	ARTICLE	IF	CITATIONS
379	Prostate Cancer Immunotherapy: Figure 1.. Clinical Cancer Research, 2011, 17, 5233-5238.	3.2	57
380	From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. Expert Review of Vaccines, 2011, 10, 743-753.	2.0	20
381	IgG Responses to Tissue-Associated Antigens as Biomarkers of Immunological Treatment Efficacy. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-10.	3.0	14
382	Immunologic Monitoring of Cellular Immune Responses in Cancer Vaccine Therapy. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-3.	3.0	4
383	Abstract 5520: Therapeutic vaccination with epitope-enhanced and wild-type TARP peptides in stage D0 prostate cancer. , 2011, , .		1
384	Abstract 5524: Generation of cellular immune responses to MUC1-C to target the portion of MUC1 that is most biologically relevant to the transformation process. , 2011, , .		0
385	Abstract SY24-02: Development of recombinant vaccines for the prevention and therapy of human carcinomas. , 2011, , .		0
386	Abstract 758: Cancer vaccine immunotherapy employing Saccharomyces cerevisiae (yeast) as a vector can modulate the balance between CD4+ T cells and regulatory T cells (Tregs) and enhance the specific antitumor immune response. , 2011, , .		0
387	Highlights on FOXO3 and tumor-associated dendritic cells in prostate cancer. Asian Journal of Andrology, 2011, 13, 657-658.	0.8	0
388	Treatment of Castration-Resistant Prostate Cancer: Updates on Therapeutics Targeting the Androgen Receptor Signaling Pathway. American Journal of Therapeutics, 2010, 17, 176-181.	0.5	8
389	New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy. Cancer Immunology, Immunotherapy, 2010, 59, 63-71.	2.0	28
390	Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunology, Immunotherapy, 2010, 59, 663-674.	2.0	279
391	Targeting the Immune System in Nonâ€“Small-Cell Lung Cancer: Bridging the Gap Between Promising Concept and Therapeutic Reality. Clinical Lung Cancer, 2010, 11, 228-237.	1.1	35
392	Vaccines as Monotherapy and in Combination Therapy for Prostate Cancer. Clinical and Translational Science, 2010, 3, 116-122.	1.5	9
393	Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2010, 28, 2070-2076.	0.8	136
394	Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2010, 28, 1099-1105.	0.8	900
395	A Viral Vaccine Encoding Prostate-Specific Antigen Induces Antigen Spreading to a Common Set of Self-Proteins in Prostate Cancer Patients. Clinical Cancer Research, 2010, 16, 4046-4056.	3.2	53
396	Reply to L. LeÃ³n et al. Journal of Clinical Oncology, 2010, 28, e417-e417.	0.8	0

#	ARTICLE	IF	CITATIONS
397	Therapeutic Cancer Vaccines in Prostate Cancer: The Paradox of Improved Survival Without Changes in Time to Progression. <i>Oncologist</i> , 2010, 15, 969-975.	1.9	131
398	Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 19-28.	1.4	32
399	An update on androgen deprivation therapy for prostate cancer. <i>Endocrine-Related Cancer</i> , 2010, 17, R305-R315.	1.6	147
400	The Current and Emerging Role of Immunotherapy in Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2010, 8, 10-16.	0.9	10
401	A Phase I Clinical Study of High Dose Ketoconazole Plus Weekly Docetaxel for Metastatic Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2010, 183, 2219-2226.	0.2	32
402	Cancer Immunology, Immunotherapeutics, and Vaccine Approaches. , 2010, , 305-319.		0
403	Phase I Study of Oral Lenalidomide in Patients With Refractory Metastatic Cancer. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 650-660.	1.0	52
404	Promising novel immunotherapies and combinations for prostate cancer. <i>Future Oncology</i> , 2009, 5, 187-196.	1.1	29
405	Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1001-1011.	1.9	187
406	Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2009, 103, 1636-1640.	1.3	112
407	Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents. <i>Cancer Investigation</i> , 2009, 27, 221-226.	0.6	115
408	A Double-Blind Randomized Crossover Study of Oral Thalidomide Versus Placebo for Androgen Dependent Prostate Cancer Treated With Intermittent Androgen Ablation. <i>Journal of Urology</i> , 2009, 181, 1104-1113.	0.2	41
409	176 Vector-based Vaccines for Cancer Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2009, 51, .	0.9	0
410	Current Perspectives in Prostate Cancer Vaccines. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2009, 9, 1052-1057.	0.9	2
411	Combining radiation and immunotherapy for synergistic antitumor therapy. <i>Current Opinion in Molecular Therapeutics</i> , 2009, 11, 37-42.	2.8	41
412	Cancer vaccines: current directions and perspectives in prostate cancer. <i>Current Opinion in Molecular Therapeutics</i> , 2009, 11, 31-6.	2.8	5
413	A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. <i>BJU International</i> , 2008, 102, 617-621.	1.3	60
414	Prostate Specific Antigen Working Group Guidelines on Prostate Specific Antigen Doubling Time. <i>Journal of Urology</i> , 2008, 179, 2181-2186.	0.2	122



#	ARTICLE	IF	CITATIONS
415	Kinetics of Serum Androgen Normalization and Factors Associated With Testosterone Reserve After Limited Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer. <i>Journal of Urology</i> , 2008, 180, 1432-1437.	0.2	36
416	Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine, Nilutamide, and Combination Therapy. <i>Clinical Cancer Research</i> , 2008, 14, 4526-4531.	3.2	141
417	A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 209-214.	3.2	174
418	Paradigm Shifts in Cancer Vaccine Therapy. <i>Experimental Biology and Medicine</i> , 2008, 233, 522-534.	1.1	43
419	Safety and Immunologic Response of a Viral Vaccine to Prostate-Specific Antigen in Combination with Radiation Therapy when Metronomic-Dose Interleukin 2 Is Used as an Adjuvant. <i>Clinical Cancer Research</i> , 2008, 14, 5284-5291.	3.2	107
420	Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 3060-3069.	3.2	208
421	Enhanced Functionality of CD4 <sup>+</sup> CD25 <sup>high</sup> FoxP3 <sup>+</sup> Regulatory T Cells in the Peripheral Blood of Patients with Prostate Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 1032-1040.	3.2	131
422	Therapeutic vaccines for prostate cancer: what have we learned?. <i>Therapy: Open Access in Clinical Medicine</i> , 2008, 5, 3-5.	0.2	1
423	Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. <i>Oncology</i> , 2008, 22, 1064-70; discussion 1075, 1080-1, 1084.	0.4	72
424	Therapeutic prostate cancer vaccines: a review of the latest developments. <i>Current Opinion in Investigational Drugs</i> , 2008, 9, 1296-301.	2.3	3
425	Cancer Vaccines: Moving Beyond Current Paradigms. <i>Clinical Cancer Research</i> , 2007, 13, 3776-3782.	3.2	367
426	The use of bisphosphonates in cancer patients. <i>Acta Oncologica</i> , 2007, 46, 581-591.	0.8	47
427	Future directions in tumor immunotherapy: CTLA4 blockade. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 136-137.	4.3	16
428	A Pilot Study of CTLA-4 Blockade after Cancer Vaccine Failure in Patients with Advanced Malignancy. <i>Clinical Cancer Research</i> , 2007, 13, 958-964.	3.2	150
429	Significant Prostate-Specific Antigen (PSA) Response to Low-Dose Ketoconazole in a Patient With Non-Metastatic Androgen-Independent Prostate Cancer (AIPC) and a Review of the Literature. <i>American Journal of Therapeutics</i> , 2007, 14, 310-313.	0.5	3
430	Enhancing efficacy of therapeutic vaccinations by combination with other modalities. <i>Vaccine</i> , 2007, 25, B89-B96.	1.7	63
431	PANVAC <sub>1</sub> -VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 543-554.	1.4	70
432	Clinical Safety of a Viral Vector Based Prostate Cancer Vaccine Strategy. <i>Journal of Urology</i> , 2007, 178, 1515-1520.	0.2	119

#	ARTICLE	IF	CITATIONS
433	Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 4957.	3.0	130
434	Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4). <i>International Journal of Cancer</i> , 2007, 121, 595-605.	2.3	19
435	Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone. <i>BJU International</i> , 2007, 99, 525-528.	1.3	7
436	Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. <i>BJU International</i> , 2007, 99, 1047-1055.	1.3	45
437	Phase I Trial of an Enhanced Prostate-Specific Antigen-Based Vaccine and Anti-CTLA-4 Antibody in Patients with Metastatic Androgen-Independent Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 347-350.	0.9	10
438	Persistent Hypocalcemia Induced by Zoledronic Acid in a Patient with Androgen-Independent Prostate Cancer and Extensive Bone Metastases. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 403-405.	0.9	16
439	PART V. Modulation of Antitumor Vaccine Strategies Preclinical and Clinical Studies of Recombinant Poxvirus Vaccines for Carcinoma Therapy. <i>Critical Reviews in Immunology</i> , 2007, 27, 451-462.	1.0	49
440	PSA-based vaccines for the treatment of prostate cancer. <i>Expert Review of Vaccines</i> , 2006, 5, 199-209.	2.0	24
441	Immunotherapy for Prostate Cancer: What's the Future?. <i>Hematology/Oncology Clinics of North America</i> , 2006, 20, 965-983.	0.9	6
442	A Randomized Phase II Study of Docetaxel Alone or in Combination with PANVAC <sub>2</sub> -V (Vaccinia) and PANVAC <sub>2</sub> -F (Fowlpox) in Patients with Metastatic Breast Cancer (NCI 05-C-0229). <i>Clinical Breast Cancer</i> , 2006, 7, 176-179.	1.1	40
443	A Pilot Trial of a Carcinoembryonic Antigen/TRICOM-Based Vaccine and Radiation to Liver Metastases in Patients with Carcinoembryonic Antigen-Positive Solid Tumors. <i>Clinical Colorectal Cancer</i> , 2006, 6, 72-75.	1.0	3
444	A Phase I Feasibility Study of an Intraprostatic Prostate-Specific Antigen-Based Vaccine in Patients with Prostate Cancer with Local Failure After Radiation Therapy or Clinical Progression on Androgen-Deprivation Therapy in the Absence of Local Definitive Therapy. <i>Clinical Genitourinary Cancer</i> , 2006, 5, 89-92.	0.9	5
445	Costimulatory Molecules as Adjuvants for Immunotherapy. <i>Frontiers in Bioscience - Landmark</i> , 2006, 11, 788.	3.0	49
446	Even More Cost Savings?. <i>Journal of Oncology Practice</i> , 2006, 2, 202-202.	2.5	0
447	Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. <i>Cancer Biology and Therapy</i> , 2006, 5, 22-27.	1.5	135
448	TRICOM Vector Based Cancer Vaccines. <i>Current Pharmaceutical Design</i> , 2006, 12, 351-361.	0.9	53
449	Early Treatment Gets the Benefit. <i>Journal of Clinical Oncology</i> , 2006, 24, 5172-5173.	0.8	2
450	Discovering Clinical Biomarkers of Ionizing Radiation Exposure with Serum Proteomic Analysis. <i>Cancer Research</i> , 2006, 66, 1844-1850.	0.4	105

#	ARTICLE	IF	CITATIONS
451	Therapeutic Vaccines for Prostate Cancer. <i>Oncologist</i> , 2006, 11, 451-462.	1.9	36
452	A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.. <i>Clinical Cancer Research</i> , 2006, 12, 1260-1269.	3.2	286
453	Prolonged Response to Nilutamide in a Patient with Stage D0.5 Prostate Cancer Who Previously Failed Androgen Deprivation Therapy. <i>American Journal of Therapeutics</i> , 2005, 12, 172-174.	0.5	4
454	A retrospective study of the time to clinical endpoints for advanced prostate cancer. <i>BJU International</i> , 2005, 96, 985-989.	1.3	102
455	Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 3353-3362.	3.2	357
456	Analyses of Recombinant Vaccinia and Fowlpox Vaccine Vectors Expressing Transgenes for Two Human Tumor Antigens and Three Human Costimulatory Molecules. <i>Clinical Cancer Research</i> , 2005, 11, 1597-1607.	3.2	44
457	Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer. <i>Future Oncology</i> , 2005, 1, 19-22.	1.1	13
458	Androgen Deprivation Therapy for Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 238.	3.8	880
459	Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen-Expressing Carcinomas. <i>Journal of Clinical Oncology</i> , 2005, 23, 720-731.	0.8	290
460	Clodronate in the prevention and treatment of skeletal metastasis. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 221-230.	1.1	5
461	A phase II study of perifosine in androgen independent prostate cancer. <i>Cancer Biology and Therapy</i> , 2005, 4, 1133-1137.	1.5	98
462	A RANDOMIZED, PHASE II TRIAL OF KETOCONAZOLE PLUS ALENDRONATE VERSUS KETOCONAZOLE ALONE IN PATIENTS WITH ANDROGEN INDEPENDENT PROSTATE CANCER AND BONE METASTASES. <i>Journal of Urology</i> , 2005, 173, 790-796.	0.2	66
463	A PROSPECTIVE ANALYSIS OF THE TIME TO NORMALIZATION OF SERUM ANDROGENS FOLLOWING 6 MONTHS OF ANDROGEN DEPRIVATION THERAPY IN PATIENTS ON A RANDOMIZED PHASE III CLINICAL TRIAL USING LIMITED HORMONAL THERAPY. <i>Journal of Urology</i> , 2005, 173, 1567-1571.	0.2	73
464	ANTIANDROGEN, VACCINE AND COMBINATION THERAPY IN PATIENTS WITH NONMETASTATIC HORMONE REFRACTORY PROSTATE CANCER. <i>Journal of Urology</i> , 2005, 174, 539-546.	0.2	106
465	A Human Cytotoxic T-Lymphocyte Epitope and Its Agonist Epitope from the Nonvariable Number of Tandem Repeat Sequence of MUC-1. <i>Clinical Cancer Research</i> , 2004, 10, 2139-2149.	3.2	60
466	Novel Therapeutic Strategies in Prostate Cancer. <i>Cancer Biology and Therapy</i> , 2004, 3, 371-376.	1.5	10
467	Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 2532-2539.	0.8	316
468	A Phase I Study of Oral CC-5013(Lenalidomide, Revlimidâ„), a Thalidomide Derivative, in Patients with Refractory Metastatic Cancer. <i>Clinical Prostate Cancer</i> , 2004, 2, 241-243.	2.1	29

#	ARTICLE	IF	CITATIONS
469	Therapeutic Vaccines for Colorectal Cancer. American Journal of Cancer, 2004, 3, 299-316.	0.4	0
470	The Emerging Role of Bisphosphonates in Prostate Cancer. American Journal of Therapeutics, 2004, 11, 60-73.	0.5	4
471	Chemotherapy for Prostate Cancer. American Journal of Therapeutics, 2004, 11, 288-294.	0.5	20
472	Vaccine Therapy for a Patient with Androgen-Insensitive Prostate Cancer without Evidence of Measurable Disease on Scans. American Journal of Therapeutics, 2004, 11, 238-241.	0.5	2
473	Increased Frequency of Venous Thromboembolism with the Combination of Docetaxel and Thalidomide in Patients with Metastatic Androgen-Independent Prostate Cancer. Pharmacotherapy, 2003, 23, 315-318.	1.2	38
474	A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1. Journal of Immunological Methods, 2003, 279, 183-192.	0.6	5
475	Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient. Urology, 2003, 62, 147-154.	0.5	12
476	Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer. Expert Review of Vaccines, 2003, 2, 483-493.	2.0	12
477	Pulmonary Toxicity During Prostate Cancer Treatment With Docetaxel and Thalidomide. American Journal of Therapeutics, 2003, 10, 228-232.	0.5	23
478	Treatment options for androgen-independent prostate cancer. Clinical Advances in Hematology and Oncology, 2003, 1, 49-57.	0.3	20
479	Novel Clinical Trials in Androgen-Independent Prostate Cancer. Clinical Prostate Cancer, 2002, 1, 51-57.	2.1	13
480	National Cancer Institute Intramural Approach to Advanced Prostate Cancer. Clinical Prostate Cancer, 2002, 1, 153-162.	2.1	8
481	Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate, 2002, 53, 109-117.	1.2	220
482	Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. Clinical Cancer Research, 2002, 8, 41-53.	3.2	66
483	A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Seminars in Oncology, 2001, 28, 62-66.	0.8	107
484	Treating systemic prostate cancer: emerging drug targets and therapies. Expert Opinion on Therapeutic Targets, 2000, 4, 751-763.	1.0	1
485	MPA &lt;sub>g</sub>;PASS&lt;/sub>; Enables Stitched Multiplex Multi-Dimensional EV Repertoire Analysis. SSRN Electronic Journal, 0, , .	0.4	0
486	HLA-A*03 is a Predictive Biomarker of Poor Response to Immune Checkpoint Blockade in Cancer. SSRN Electronic Journal, 0, , .	0.4	0